When CADTH’s first Call for Patient Input was issued in May 2010, three patient groups answered: Arthritis Consumer Experts, Canadian Arthritis Patient Alliance, and The Arthritis Society. The groups provided insight and their unique perspectives into the CADTH Common Drug Review’s (CDR) assessment of Actemra.

Since then, we have received 297 patient input submissions to CDR, which have contributed to 142 final recommendations for the drug to be reimbursed, or not, by our publicly funded drug plans.

As well, since its inception, CADTH’s pan-Canadian Oncology Drug Review (pCODR) program has incorporated patient perspectives into the review reports and committee deliberations. As of March 31, 2015, pCODR has received 75 patient input submissions, allowing 53 of the 56 completed pCODR reviews to directly incorporate patient perspectives. In addition, approximately 63% of patient groups participate in the feedback on pCODR Expert Review Committee’s initial recommendations. As of March 2015, pCODR has issued 43 final recommendations.

For more details, go to:https://www.cadth.ca/cdr/patient-input/updates-patient-groups